Key facts
- This page summarizes Terry-Ann Burrell's Form 4 filing for Beam Therapeutics Inc. (BEAM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Apr 2024, 16:10.
Terry-Ann Burrell - 26 Apr 2024 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- BEAM
- Reported as of
- 26 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Apr 2024, 16:10:23 UTC
- Prior SEC filing
- 03 Apr 2024
- Next SEC filing
- 05 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Christine Bellon, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Terry-Ann Burrell filed Form 4 for Beam Therapeutics Inc. (BEAM) on 29 Apr 2024.
Change
- Previous filing in this sequence was filed on 03 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BEAM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- +18%
- Price
- $0.000000
- Shares after
- 82,637
- Date
- 26 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BEAM
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 26 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $30.87
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSU vests in three substantially equal annual installments on each of the first three anniversaries of September 30, 2023, subject to the Reporting Person's continued service with BEAM through each vesting date.
Footnote F2
This stock option vests in equal monthly installments each month following July 31, 2023 for the subsequent thirty-six months, subject to the Reporting Person's continued service with BEAM through each vesting date.